Kyoko Takahashi Lin

Davis Polk advised Pactiv Evergreen Inc. (formerly known as Reynolds Group Holdings Limited) on its $574 million initial public offering of 41,026,000 shares of common stock. The shares of…

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…

Davis Polk is advising Clarivate Plc on its approximately $6.8 billion combination with CPA Global. In the all-stock transaction, CPA Global shareholders will receive approximately 218…

Davis Polk advised Pattern Energy Operations LP and Pattern Energy Operations Inc. on their Rule 144A/Regulation S offering of $700 million aggregate principal amount of 4.500% senior notes…

Davis Polk advised BRP Group, Inc. on its $175.2 million follow-on offering of 13,225,000 shares of Class A common stock, which includes 1,725,000 shares from the full exercise of the…

Davis Polk advised Clarivate Plc in connection with the $1.08 billion SEC-registered offering of 48,000,000 of its ordinary shares, of which 14,000,000 ordinary shares were issued and sold…

Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which included the exercise in full by the underwriters of their option to…

Davis Polk is advising Mobile Mini, Inc. on its all-stock merger of equals with WillScot Corporation to form a combined company with an implied total enterprise value of approximately $6.6…